INTRODUCTION

SCHEMA

  The meeting was financially supported by

ELI LILLY (FINLAND)
NOVO NORDISK (FINLAND)

and

Novartis (Finland)
Aventis (Finland)
MSD (Finland)
AstraZeneca (Sweden)
Pyrosequencing (Sweden)
Leiras (Finland) 		MAP

INTRODUCTION

SCHEMA